+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type, By Service (Process Development & Optimization, Manufacturing Services), By End-user, By Application, By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 150 Pages
  • September 2023
  • Region: Global
  • Grand View Research
  • ID: 5893100
The global nucleic acid therapeutics CDMO market size is expected to reach USD 22.42 billion by 2030, advancing at a CAGR of 9.4% from 2023 to 2030. The market's growth is primarily attributed to factors such as increasing demand for nucleic acid therapeutics, advancements in nucleic acid technologies, and rising FDA approvals of nucleic acid therapeutics, propelling the need for cost-effective contract development and manufacturing services.

Growing investment and interest in gene therapy research and development by biotechnology companies, pharmaceutical firms, and academic institutions are driving the demand for CDMO services. CDMOs have played a crucial role in gene therapy manufacturing. For instance, Catalent has taken on the primary role as the commercial manufacturing partner for Sarepta Therapeutics in their efforts to advance gene therapy solutions.

The success of mRNA vaccines in responding to the COVID-19 pandemic has showcased the potential of nucleic acid therapeutics, stimulating further research and investment in this field. For instance, in March 2022, Sanofi announced that it plans to allocate USD 1.02 billion (935 million euros) for the development of messenger RNA vaccines in France over the coming years. Sanofi intends to allocate this investment until 2026 as a part of a 2-billion-euro global investment initiative unveiled in June 2021. This initiative is designed to expedite the company's mRNA strategy. Such increased funding scenarios drive market growth.

Furthermore, increasing incidences of CDMO acquisitions and partnerships are expected to accelerate the market growth for nucleic acid therapeutics CDMO in the coming years. For instance, in May 2022, eureKARE initiated a merger worth USD 160.98 million (€150 million) to create a cell & gene therapy contract development and manufacturing organization (CDMO).

The company has established eureKING, a Special Purpose Acquisition Company (SPAC), with the aim of merging three European Contract Development and Manufacturing Organizations (CDMOs) into a unified entity. In another instance, in April 2022, Fujifilm broadened its Advanced Therapies Contract Development and Manufacturing Organization (CDMO) portfolio by acquiring a specialized cell therapy manufacturing facility from Atara Biotherapeutics, Inc. located in California. Such initiatives are expected to boost market growth.

Nucleic Acid Therapeutics CDMO Market Report Highlights

  • The RNA-based therapies segment held the largest revenue share in 2022. RNA-based therapies, mainly mRNA, offer versatility in addressing various diseases. They can be designed to produce a variety of therapeutic proteins, making them applicable to diverse therapeutic areas
  • The gene therapy segment is expected to show significant market growth in the coming years. This is attributed to the clinical success of gene therapies, which have helped in expanding indications of gene therapies
  • In 2022, the manufacturing services segment dominated the market, accounting for over 38% of the total revenue share. Key factors contributing to segment growth include complex manufacturing processes, scale-up & production challenges, and cost efficiency
  • The biotechnology companies held a major revenue share of over 58% in 2022 due to substantial investments in the research and development of innovative therapies
  • By application, the oncology segment led the global market with a revenue share of over 31.0% in 2022. This is attributed to the rising adoption of gene therapy and RNA-based therapeutics and the increasing pipeline of nucleic acid therapeutics for oncology
  • North America held the largest revenue share of 38.49% in the nucleic acid therapeutic CDMO market in 2022. Substantial investments and funding support, strong academic and research institutions, and global expansion of CDMOs drive regional growth


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.5. Market Driver Analysis
3.6. Market Restraint Analysis
3.7. Business Environment Analysis
3.7.1. SWOT Analysis
3.7.2. Porter’s Five Forces Analysis
3.8. COVID-19 Impact Analysis
Chapter 4. Type Business Analysis
4.1. Nucleic Acid Therapeutics CDMO Market: Type Movement Analysis
4.2. Gene Therapy
4.2.1. Gene Therapy Market, 2018 - 2030 (USD Billion)
4.3. RNA-based Therapies
4.3.1. RNA-based Therapies Market, 2018 - 2030 (USD Billion)
Chapter 5. Service Business Analysis
5.1. Nucleic Acid Therapeutics CDMO Market: Service Movement Analysis
5.2. Process Development and Optimization
5.2.1. Process Development and Optimization Market, 2018 - 2030 (USD Billion)
5.3. Manufacturing Services
5.3.1. Manufacturing Services Market, 2018 - 2030 (USD Billion)
5.4. Analytical and Quality Control Services
5.4.1. Analytical and Quality Control Services Market, 2018 - 2030 (USD Billion)
5.5. Others
5.5.1. Others Market, 2018 - 2030 (USD Billion)
Chapter 6. End Users Business Analysis
6.1. Nucleic Acid Therapeutics CDMO Market: End Users Movement Analysis
6.2. Pharmaceutical Companies
6.2.1. Pharmaceutical Companies Market, 2018 - 2030 (USD Billion)
6.3. Government & Academic Research Institutes
6.3.1. Government & Academic Research Institutes Market, 2018 - 2030 (USD Billion)
6.4. Biotech Companies
6.4.1. Biotech Companies Market, 2018 - 2030 (USD Billion)
Chapter 7. Application Business Analysis
7.1. Nucleic Acid Therapeutics CDMO Market: Application Movement Analysis
7.2. Oncology
7.2.1. Oncology Market, 2018 - 2030 (USD Billion)
7.3. Genetic Disorders
7.3.1. Genetic Disorders Market, 2018 - 2030 (USD Billion)
7.4. Infectious Diseases
7.4.1. Infectious Diseases Market, 2018 - 2030 (USD Billion)
7.5. Others
7.5.1. Others Market, 2018 - 2030 (USD Billion)
Chapter 8. Regional Business Analysis
8.1. Nucleic Acid Therapeutics CDMO Market Share by Region, 2022 & 2030
8.2. North America
8.2.1. North America Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.2.2. U.S.
8.2.2.1. Key Country Dynamics
8.2.2.2. Regulatory Framework
8.2.2.3. Competitive Scenario
8.2.2.4. U.S. Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.2.3. Canada
8.2.3.1. Key Country Dynamics
8.2.3.2. Regulatory Framework
8.2.3.3. Competitive Scenario
8.2.3.4. Canada Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.3. Europe
8.3.1. Europe Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.3.2. UK
8.3.2.1. Key Country Dynamics
8.3.2.2. Competitive Scenario
8.3.2.3. UK Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.3.3. Germany
8.3.3.1. Key Country Dynamics
8.3.3.2. Competitive Scenario
8.3.3.3. Germany Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.3.4. France
8.3.4.1. Key Country Dynamics
8.3.4.2. Competitive Scenario
8.3.4.3. France Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.3.5. Italy
8.3.5.1. Key Country Dynamics
8.3.5.2. Competitive Scenario
8.3.5.3. Italy Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.3.6. Spain
8.3.6.1. Key Country Dynamics
8.3.6.2. Competitive Scenario
8.3.6.3. Spain Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.3.7. Sweden
8.3.7.1. Key Country Dynamics
8.3.7.2. Competitive Scenario
8.3.7.3. Sweden Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.3.8. Norway
8.3.8.1. Key Country Dynamics
8.3.8.2. Competitive Scenario
8.3.8.3. Norway Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.3.9. Denmark
8.3.9.1. Key Country Dynamics
8.3.9.2. Competitive Scenario
8.3.9.3. Denmark Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.4. Asia Pacific
8.4.1. Asia Pacific Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.4.2. Japan
8.4.2.1. Key Country Dynamics
8.4.2.2. Competitive Scenario
8.4.2.3. Japan Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.4.3. China
8.4.3.1. Key Country Dynamics
8.4.3.2. Competitive Scenario
8.4.3.3. China Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.4.4. India
8.4.4.1. Key Country Dynamics
8.4.4.2. Competitive Scenario
8.4.4.3. India Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.4.5. Australia
8.4.5.1. Key Country Dynamics
8.4.5.2. Competitive Scenario
8.4.5.3. Australia Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.4.6. South Korea
8.4.6.1. Key Country Dynamics
8.4.6.2. Competitive Scenario
8.4.6.3. South Korea Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.4.7. Thailand
8.4.7.1. Key Country Dynamics
8.4.7.2. Competitive Scenario
8.4.7.3. Thailand Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.5. Latin America
8.5.1. Latin America Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.5.2. Brazil
8.5.2.1. Key Country Dynamics
8.5.2.2. Competitive Scenario
8.5.2.3. Brazil Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.5.3. Mexico
8.5.3.1. Key Country Dynamics
8.5.3.2. Competitive Scenario
8.5.3.3. Mexico Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.5.4. Argentina
8.5.4.1. Key Country Dynamics
8.5.4.2. Competitive Scenario
8.5.4.3. Argentina Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.6. MEA
8.6.1. MEA Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.6.2. South Africa
8.6.2.1. Key Country Dynamics
8.6.2.2. Competitive Scenario
8.6.2.3. South Africa Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.6.3. Saudi Arabia
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Saudi Arabia Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.6.4. UAE
8.6.4.1. Key Country Dynamics
8.6.4.2. Competitive Scenario
8.6.4.3. UAE Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
8.6.5. Kuwait
8.6.5.1. Key Country Dynamics
8.6.5.2. Competitive Scenario
8.6.5.3. Kuwait Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Chapter 9. Competitive Landscape
9.1. Company Categorization
9.2. Strategy Mapping
9.2.1. Mergers & Acquisitions
9.2.2. Collaborations
9.2.3. New Product Launches
9.3. Participant’s overview
9.3.1. Catalent
9.3.1.1. Overview
9.3.1.2. Financial Performance
9.3.1.3. Product Benchmarking
9.3.1.4. Strategic Initiatives
9.3.2. Thermo Fisher Scientific
9.3.2.1. Overview
9.3.2.2. Financial Performance
9.3.2.3. Product Benchmarking
9.3.2.4. Strategic Initiatives
9.3.3. Lonza
9.3.3.1. Overview
9.3.3.2. Financial Performance
9.3.3.3. Product Benchmarking
9.3.3.4. Strategic Initiatives
9.3.4. FUJIFILM Diosynth Biotechnologies
9.3.4.1. Overview
9.3.4.2. Financial Performance
9.3.4.3. Product Benchmarking
9.3.4.4. Strategic Initiatives
9.3.5. Cognate BioServices
9.3.5.1. Overview
9.3.5.2. Financial Performance
9.3.5.3. Product Benchmarking
9.3.5.4. Strategic Initiatives
9.3.6. Eurofins Genomics
9.3.6.1. Overview
9.3.6.2. Financial Performance
9.3.6.3. Product Benchmarking
9.3.6.4. Strategic Initiatives
9.3.7. Sirion Biotech
9.3.7.1. Overview
9.3.7.2. Financial Performance
9.3.7.3. Product Benchmarking
9.3.7.4. Strategic Initiatives
9.3.8. Oxford Biomedica
9.3.8.1. Overview
9.3.8.2. Financial Performance
9.3.8.3. Product Benchmarking
9.3.8.4. Strategic Initiatives
9.3.9. Danaher (Aldevron)
9.3.9.1. Overview
9.3.9.2. Financial Performance
9.3.9.3. Product Benchmarking
9.3.9.4. Strategic Initiatives
List of Tables
Table 1 List of data sources
Table 2 Global Nucleic Acid Therapeutics CDMO Market, by region, 2018 - 2030 (USD Billion)
Table 3 Global Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 4 Global Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 5 Global Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 6 Global Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 7 North America Nucleic Acid Therapeutics CDMO Market, by country, 2018 - 2030 (USD Billion)
Table 8 North America Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 9 North America Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 10 North America Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 11 North America Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 12 U.S. Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 13 U.S. Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 14 U.S. Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 15 U.S. Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 16 Canada Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 17 Canada Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 18 Canada Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 19 Canada Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 20 Europe Nucleic Acid Therapeutics CDMO Market, by country, 2018 - 2030 (USD Billion)
Table 21 Europe Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 22 Europe Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 23 Europe Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 24 Europe Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 25 UK Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 26 UK Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 27 UK Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 28 UK Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 29 Germany Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 30 Germany Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 31 Germany Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 32 Germany Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 33 France Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 34 France Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 35 France Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 36 France Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 37 Italy Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 38 Italy Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 39 Italy Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 40 Italy Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 41 Spain Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 42 Spain Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 43 Spain Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 44 Sapin Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 45 Denmark Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 46 Denmark Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 47 Denmark Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 48 Denmark Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 49 Sweden Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 50 Sweden Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 51 Sweden Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 52 Sweden Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 53 Norway Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 54 Norway Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 55 Norway Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 56 Norway Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 57 Asia Pacific Nucleic Acid Therapeutics CDMO Market, by country, 2018 - 2030 (USD Billion)
Table 58 Asia Pacific Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 59 Asia Pacific Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 60 Asia Pacific Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 61 Asia Pacific Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 62 Japan Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 63 Japan Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 64 Japan Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 65 Japan Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 66 China Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 67 China Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 68 China Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 69 China Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 70 India Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 71 India Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 72 India Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 73 India Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 74 South Korea Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 75 South Korea Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 76 South Korea Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 77 South Korea Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 78 Australia Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 79 Australia Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 80 Australia Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 81 Australia Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 82 Thailand Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 83 Thailand Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 84 Thailand Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 85 Thailand Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 86 Latin America Nucleic Acid Therapeutics CDMO Market, by country, 2018 - 2030 (USD Billion)
Table 87 Latin America Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 88 Latin America Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 89 Latin America Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 90 Latin America Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 91 Brazil Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 92 Brazil Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 93 Brazil Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 94 Brazil Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 95 Mexico Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 96 Mexico Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 97 Mexico Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 98 Mexico Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 99 Argentina Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 100 Argentina Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 101 Argentina Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 102 Argentina Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 103 MEA Nucleic Acid Therapeutics CDMO Market, by country, 2018 - 2030 (USD Billion)
Table 104 MEA Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 105 MEA Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 106 MEA Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 107 MEA Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 108 South Africa Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 109 South Africa Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 110 South Africa Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 111 South Africa Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 112 Saudi Arabia Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 113 Saudi Arabia Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 114 Saudi Arabia Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 115 Saudi Arabia Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 116 UAE Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 117 UAE Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 118 UAE Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 119 UAE Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 120 Kuwait Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
Table 121 Kuwait Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
Table 122 Kuwait Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
Table 123 Kuwait Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
Table 124 Participant’s overview
Table 125 Financial performance
Table 126 Type benchmarking
Table 127 Strategic Initiatives
List of Figures
Fig. 1 Market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Market research approaches
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment.
Fig. 7 Market formulation & validation
Fig. 8 Nucleic Acid Therapeutics CDMO Market revenue, 2018-2030 (USD Billion)
Fig. 9 Nucleic Acid Therapeutics CDMO Market Snapshot
Fig. 10 Nucleic Acid Therapeutics CDMO Market driver impact
Fig. 11 Nucleic Acid Therapeutics CDMO Market Restraint Impact
Fig. 12 Porter’s 5 Forces Analysis
Fig. 13 PESTEL Analysis
Fig. 14 Global Nucleic Acid Therapeutics CDMO Market: Type Movement Analysis
Fig. 15 Global Nucleic Acid Therapeutics CDMO Market: Type Key Takeaways
Fig. 16 Global Gene Therapy Market, 2018 - 2030 (USD Billion)
Fig. 17 Global RNA-based Therapies Market, 2018 - 2030 (USD Billion)
Fig. 18 Global Nucleic Acid Therapeutics CDMO Market: Service Movement Analysis
Fig. 19 Global Nucleic Acid Therapeutics CDMO Market: Service Key Takeaways
Fig. 20 Global Process Development and Optimization Market, 2018 - 2030 (USD Billion)
Fig. 21 Global Manufacturing Services Market, 2018 - 2030 (USD Billion)
Fig. 22 Global Analytical and Quality Control Services Market, 2018 - 2030 (USD Billion)
Fig. 23 Global Others Market, 2018 - 2030 (USD Billion)
Fig. 24 Global Nucleic Acid Therapeutics CDMO Market: End Users Movement Analysis
Fig. 25 Global Nucleic Acid Therapeutics CDMO Market: End Users Key Takeaways
Fig. 26 Pharmaceutical Companies Market, 2018 - 2030 (USD Billion)
Fig. 27 Government & Academic Research Institute Market, 2018 - 2030 (USD Billion)
Fig. 28 Biotech Companies Market, 2018 - 2030 (USD Billion)
Fig. 29 Global Nucleic Acid Therapeutics CDMO Market: Application Movement Analysis
Fig. 30 Global Nucleic Acid Therapeutics CDMO Market: Application Key Takeaways
Fig. 31 Oncology Market, 2018 - 2030 (USD Billion)
Fig. 32 Genetic Disorders Market, 2018 - 2030 (USD Billion)
Fig. 33 Infectious Diseases Market, 2018 - 2030 (USD Billion)
Fig. 34 Others Market, 2018 - 2030 (USD Billion)
Fig. 35 Regional Marketplace: Key Takeaways
Fig. 36 Regional Outlook, 2022 & 2030
Fig. 37 North America Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 38 U.S. Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 39 Canada Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 40 Europe Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 41 Germany Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 42 UK Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 43 France Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 44 Italy Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 45 Spain Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 46 Denmark Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 47 Norway Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 48 Sweden Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 49 Asia Pacific Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 50 Japan Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 51 China Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 52 India Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 53 Australia Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 54 South Korea Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 55 Thailand Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 56 Latin America Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 57 Brazil Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 58 Mexico Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 59 Argentina Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 60 Middle East and Africa Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 61 South Africa Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 62 Saudi Arabia Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 63 UAE Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 64 Kuwait Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
Fig. 65 Market participant categorization
Fig. 66 Heat map analysis

Companies Mentioned

  • Catalent
  • Thermo Fisher Scientific
  • Lonza
  • FUJIFILM Diosynth Biotechnologies
  • Cognate BioServices
  • Eurofins Genomics
  • Sirion Biotech
  • Oxford Biomedica
  • Danaher (Aldevron)

Methodology

Loading
LOADING...

Table Information